BofA Lowers PT on Biogen (BIIB) to $142 From $143, Keeps a Neutral Rating

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on Biogen Inc. (NASDAQ:BIIB) to $142 from $143 on August 1, keeping a Neutral rating on the shares.

Biogen Inc. (BIIB): Among Small-Cap Healthcare Stocks Hedge Funds is Buying

A patient receiving physical therapy for a neurological disease.

The firm told investors that Biogen Inc.’s (NASDAQ:BIIB) 2025 estimates are “slightly higher” after a “big beat and raise” in fiscal Q2 2025. However, it added that the company trimmed its price target, rolling its valuation to its 2026 EPS estimate.

BofA further stated that while Biogen Inc. (NASDAQ:BIIB) is “admittedly one of the cheaper names in large-cap biopharma,” the company is struggling to see a compelling “buy thesis” as the growth outlook over the next few years “remains lackluster.”

Biogen Inc. (NASDAQ:BIIB) is a global biopharmaceutical company that discovers, develops, and delivers advanced therapies for serious diseases worldwide.

Its medicine portfolio treats multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).

While we acknowledge the potential of BIIB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BIIB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.